Jan Wald
Jan Wald
boston buying good insider investors scientific
I think investors do take insider buying as a good sign, and I think they especially wanted Boston Scientific to do it.
along believe boston deal matter small strategic
I don't believe these things are going to matter for Boston Scientific. This is a strategic deal for them and these are small perturbations along the way.
boston deal power reach scientific
Boston Scientific will do everything in its power to reach a deal with Guidant.
boston company fda gain permit product quality saying scientific seemed until
What the FDA seemed to be saying is that it doesn't know if Boston Scientific has a systemic, corporate-wide quality policy, and until it does the FDA will not permit the company to gain product approvals in adulterated plants.
accept board boston clearing price scientific terms
The price wasn't as important as clearing up some terms and conditions. If Boston Scientific has done that, then I don't know why Guidant's board wouldn't accept this bid.
boston heard scientific single
I haven't heard from a single Guidant shareholder who doesn't like the Boston Scientific deal.
boston less time worse
The less time they give Boston Scientific, the worse it is for Boston Scientific. They have less time to react.
ask boston hold holding johnson paper rather whether
If you're a Guidant shareholder, you have to ask yourself whether you'd rather hold Boston paper or Johnson & Johnson paper. I would rather hold Boston, because I'm holding Guidant for growth.
company hard indication processes
It is another indication that the processes could have been better ? but the company is working hard on it already.
actions company eventually expenses given remain stay
I think there are some actions the company will have to take and some expenses the company will have to incur that will make it tough. I still think given those parameters, it can be, stay and remain an independent company and eventually flourish.
growth jude needs people thinking walk
J&J needs something like Guidant to revitalize its growth. People are now thinking that if J&J does walk away, St. Jude is in their scopes.
needs
J&J needs something like Guidant to revitalize its growth,
hard people work
People are Guidant's most important asset, ... so there are hard trade-offs for Guidant to work through.
appears doctors faster fresh good perhaps portion willing
It appears that a good portion of doctors are willing to give Guidant a fresh look in their practices, and perhaps faster than most believed.